Crowdonomics
All companies

Stella Diagnostics, Inc.

Operating

Healthcare · Salt Lake City, UT

Estimated pre-money ⓘ
$101.1M
As of Oct 2020 · from Reg A Offering (2020) · our estimate: offering price × shares outstanding, not a stated valuation
Total raised
$0
Across 1 round since 2020
Latest share price
$5.00
Reg A Offering (2020) offering price

Financials

FY2019–FY2020 · from SEC filings · hover any figure for its source
$0
−$169K
2019
$0
−$262K
2020
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2019
FY2020
Income statement
Revenue
$0
$0
Cost of goods sold
$72,185
$164,846
Net income
-$168,738
-$262,054
Balance sheet
Cash
$37,475
$37,473
Accounts receivable
$0
$0
Total assets
$37,475
$39,807
Long-term debt
$317,286
$252,286
Total liabilities
$10,489,380
$10,585,028
Other
Headcount
1
1

Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.

Valuation over rounds

Pre-money — the valuation set before each round’s money came in
$101.1M
est. pre-money
Reg A+ · Equity · Oct 2020

Dotted grey bars are our estimate for rounds that didn't state one: the round's share price × the shares outstanding in its filings. Same measure as blue, but rougher.

Cap table

Share counts as of Jun 15, 2022
Series D Preferred Stock · 4.52%Series A Preferred · 0%Common Stock · 95.5%
ClassOutstandingVotes / shareConvertsAs convertedLiquidationLast price
Series D Preferred Stockpreferred927,514—5 × Common Stock4.52%1× · paid 1st—
Series A Preferredpreferred100,000—0 × Common Stock0%——
Common Stock98,029,513——95.5%——
Total99,057,027102,667,093 as converted100%

Shares outstanding over timein today's share terms

99M49M0
Dec 2019Jun 2022
Common StockSeres A Preferred StockSeries A PreferredSeries D Preferred Stock

Changes in named holdersshares in today's terms · % of all shares at the time

Principal holders% as the filing states it, Jun 15, 2022

  • White Birch Portal, LLC261,600 Series D Preferred Stock31.6%of Series D Preferred
  • Israel Levy Revocable Trust147,754 Series D Preferred Stock16.3%of Series D Preferred
  • DASA Portal113,760 Series D Preferred Stock13.7%of Series D Preferred
  • Arie Maor96,000 Series D Preferred Stock11.6%of Series D Preferred
  • Albert Levy72,000 Series D Preferred Stock8.7%of Series D Preferred
  • Jay Parikh50,400 Series D Preferred Stock6.09%of Series D Preferred
  • Noah N. Levy12,000 Series D Preferred Stock5.8%of Series D Preferred
  • Daniel Abramson45,600 Series D Preferred Stock5.51%of Series D Preferred
  • Keystone Capital Partners, LLC36,000 Series D Preferred Stock4.35%of Series D Preferred
  • Martin Enterprises34,800 Series D Preferred Stock4.2%of Series D Preferred
  • Ilan Grinberg33,600 Series D Preferred Stock4.06%of Series D Preferred
  • Daniel Dorman12,000 Series D Preferred Stock1.45%of Series D Preferred
  • Mastiff Group, LLC12,000 Series D Preferred Stock1.26%of Series D Preferred

From the company's SEC filings: share counts per class, each class's voting and conversion terms, and the holders of 20% or more that Form C requires (officers and 10%+ holders on Form 1-A). Filings name only large holders, so most owners — including crowd investors — are not listed, and a holder's percentage may be of its own class rather than of the whole company. “As converted” counts each class in the shares it converts into. Prices and crowd share counts are in today's share terms — adjusted for splits and conversions since they were sold. Hover a figure for its filing.

Fundraising history

Reg A+ · Equity · Oct 2020Closedvia DALMORE GROUP LLC
Raised $0 / $15.4MEst. pre-money $101.1M

Team

5 people
Joe Abdo
Director and Chief Executive Officer
Dr. Devendra K. Agrawal
Scientific Advisor
Dr. Sumeet Mittal
Clinical Advisor
Daniel Wainstein
Director
Marissa Welner
Director

Names and titles as disclosed on SEC Form 1-A. Bios and photos come from the platform campaign page and may be out of date.

  • Form QUALIFJun 22, 20229999999994-22-000225
    EDGAR
  • Form 1-A POSJun 15, 20220001477932-22-004417
    EDGAR
  • Form 253G2Apr 8, 20220001477932-22-002149
    EDGAR
  • Form 253G2Feb 10, 20220001477932-22-000649
    EDGAR
  • Form QUALIFJun 23, 20219999999994-21-000175
    EDGAR
  • Form 1-A/AMay 10, 20210001477932-21-002980
    EDGAR
  • Form 1-A/AMar 26, 20210001477932-21-001717
    EDGAR
  • Form 1-A/ADec 11, 20200001477932-20-007215
    EDGAR
Source: SEC EDGARCIK 0001827620WYShare price $5.00Last synced Aug 16, 2026

About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.